- cafead Jul 01, 2024 at 11:32: AM
via Capricor Therapeutics has announced its deramiocel cell therapy continues to be safe and effective after three years for Duchenne muscular dystrophy (DMD).
The Phase II (NCT03406780) three-year open-label extension (OLE) study showed that deramiocel led to a 47% slowing of disease in skeletal muscle in patients with DMD.
article source
The Phase II (NCT03406780) three-year open-label extension (OLE) study showed that deramiocel led to a 47% slowing of disease in skeletal muscle in patients with DMD.
article source